Key Points
- Medifast director Scott Schlackman bought 2,500 shares of MED on May 11 at an average price of $12.53, a purchase worth about $31,325. This increased his direct holdings by 8.91% to 30,549 shares.
- Schlackman also bought 2,500 shares on May 8 at $12.65 per share, showing continued insider buying in the stock over consecutive trading days.
- Medifast recently reported quarterly EPS of -$0.19, beating expectations, and revenue of $76.04 million, above estimates. Despite the beat, analysts still have a consensus rating of Reduce with a $12 price target.
Medifast Inc (NYSE:MED - Get Free Report) Director Scott Schlackman acquired 2,500 shares of the stock in a transaction dated Monday, May 11th. The shares were bought at an average price of $12.53 per share, with a total value of $31,325.00. Following the completion of the purchase, the director directly owned 30,549 shares of the company's stock, valued at approximately $382,778.97. This trade represents a 8.91% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link.
Scott Schlackman also recently made the following trade(s):
- On Friday, May 8th, Scott Schlackman bought 2,500 shares of Medifast stock. The stock was purchased at an average price of $12.65 per share, with a total value of $31,625.00.
Medifast Stock Performance
Shares of MED opened at $12.56 on Wednesday. The stock has a 50-day moving average of $10.66 and a two-hundred day moving average of $11.09. The stock has a market cap of $139.62 million, a P/E ratio of -6.86 and a beta of 0.55. Medifast Inc has a one year low of $9.22 and a one year high of $15.46.
Medifast (NYSE:MED - Get Free Report) last released its earnings results on Monday, May 4th. The specialty retailer reported ($0.19) EPS for the quarter, topping analysts' consensus estimates of ($0.55) by $0.36. Medifast had a negative return on equity of 4.80% and a negative net margin of 5.78%.The firm had revenue of $76.04 million during the quarter, compared to the consensus estimate of $69.20 million. Medifast has set its FY 2026 guidance at -2.750--1.550 EPS and its Q2 2026 guidance at -1.000--0.500 EPS. Analysts predict that Medifast Inc will post -2 EPS for the current fiscal year.
Institutional Investors Weigh In On Medifast
Large investors have recently modified their holdings of the business. BNP Paribas Financial Markets grew its position in shares of Medifast by 103.1% in the third quarter. BNP Paribas Financial Markets now owns 2,338 shares of the specialty retailer's stock valued at $32,000 after purchasing an additional 1,187 shares in the last quarter. Quantbot Technologies LP acquired a new position in Medifast during the third quarter worth $37,000. Intesa Sanpaolo Wealth Management purchased a new stake in Medifast in the 4th quarter valued at $47,000. State of Wyoming purchased a new stake in Medifast in the 4th quarter valued at $59,000. Finally, Strs Ohio acquired a new stake in shares of Medifast in the 1st quarter worth $78,000. Hedge funds and other institutional investors own 95.51% of the company's stock.
Wall Street Analysts Forecast Growth
A number of research firms have weighed in on MED. Stephens reduced their price objective on Medifast from $15.00 to $12.00 and set an "equal weight" rating for the company in a research note on Thursday, February 19th. Wall Street Zen upgraded Medifast from a "sell" rating to a "hold" rating in a research report on Saturday, March 21st. Finally, Weiss Ratings downgraded Medifast from a "sell (d-)" rating to a "sell (e+)" rating in a report on Wednesday, May 6th. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Reduce" and a consensus target price of $12.00.
Check Out Our Latest Report on MED
Medifast Company Profile
(
Get Free Report)
Medifast, Inc (NYSE: MED) is a health and wellness company specializing in clinically supported weight-loss, weight-management and healthy living products and services. Through its OPTAVIA brand, the company offers a range of meal replacement products, snacks, supplements and coaching programs designed to support metabolic health and sustainable lifestyle changes. Medifast markets its products directly to consumers via a network of independent distributors—known as OPTAVIA Coaches—who provide personalized guidance and support throughout the client's weight‐loss journey.
Founded in 1980 by William Vitale and headquartered in Baltimore, Maryland, Medifast has grown into a nationally recognized provider of nutrition and weight‐management solutions.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
